IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Momentum Continues with Presentations at ASCO and ESMO Imunon, Inc.

These 10 Firms Crushed The Market Last Week. In this article, we are going to take a look at where Imunon, Inc. (NASDAQ:IMNN) ...

Outstanding Phase 2 Results will be discussed at the 2025 ASCO in an Oral Presentation and featured in peer reviewed medical journal Gynecologic Oncology Phase 3 OVATION 3 Study in progress ...

Imunon, Inc. (NASDAQ:IMNN) has completed a private placement, securing $3.25 million in initial funding by selling 7,222,223 ...

In the run up to the 2025 annual ASCO meeting, IMUNON (Nasdaq: IMNN) is moving into a Phase III trial with its lead candidate ...

LAWRENCEVILLE, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that an ...

A New Jersey-based biotech company stole the show to finish out the week after the company announced new data from its Phase ...

LAWRENCEVILLE, N.J., March 24, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the U ...

The phase 3 OVATION 3 trial will evaluate IMNN-001's efficacy and safety in advanced ovarian cancer patients, comparing it with standard chemotherapy. Phase 2 results demonstrated a 35% improvement in ...